Authors' Affiliations: Pancreatic Cancer Unit, Laboratory of Human Carcinogenesis, Center for Cancer Research, Genetics Branch, National Cancer Institute, NIH, Bethesda; Pathology and Laboratory Medicine, Baltimore Veterans Affairs Medical Center, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Division of Surgical Oncology, The Department of Surgery and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland; and Department of General and Visceral Surgery, University Medicine, Göttingen, Germany.
Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5.
To identify metabolic pathways that are perturbed in pancreatic ductal adenocarcinoma (PDAC), we investigated gene-metabolite networks with integration of metabolomics and transcriptomics.
We conducted global metabolite profiling analysis on two independent cohorts of resected PDAC cases to identify critical metabolites alteration that may contribute to the progression of pancreatic cancer. We then searched for gene surrogates that were significantly correlated with the key metabolites, by integrating metabolite and gene expression profiles.
Fifty-five metabolites were consistently altered in tumors as compared with adjacent nontumor tissues in a test cohort (N = 33) and an independent validation cohort (N = 31). Weighted network analysis revealed a unique set of free fatty acids (FFA) that were highly coregulated and decreased in PDAC. Pathway analysis of 157 differentially expressed gene surrogates revealed a significantly altered lipid metabolism network, including key lipolytic enzymes PNLIP, CLPS, PNLIPRP1, and PNLIPRP2. Gene expressions of these lipases were significantly decreased in pancreatic tumors as compared with nontumor tissues, leading to reduced FFAs. More importantly, a lower gene expression of PNLIP in tumors was associated with poorer survival in two independent cohorts. We further showed that two saturated FFAs, palmitate and stearate, significantly induced TRAIL expression, triggered apoptosis, and inhibited proliferation in pancreatic cancer cells.
Our results suggest that impairment in a lipolytic pathway involving lipases, and a unique set of FFAs, may play an important role in the development and progression of pancreatic cancer and provide potential targets for therapeutic intervention.
为了鉴定胰腺导管腺癌(PDAC)中发生紊乱的代谢途径,我们将代谢组学和转录组学整合起来研究基因-代谢物网络。
我们对两个独立的 PDAC 病例切除队列进行了全局代谢物谱分析,以鉴定可能导致胰腺癌进展的关键代谢物改变。然后,我们通过整合代谢物和基因表达谱,寻找与关键代谢物显著相关的基因替代物。
在一个测试队列(N=33)和一个独立验证队列(N=31)中,与相邻非肿瘤组织相比,肿瘤中有 55 种代谢物发生了一致性改变。加权网络分析显示,一组独特的游离脂肪酸(FFA)在 PDAC 中高度协同调节并减少。对 157 个差异表达基因替代物的通路分析显示,脂质代谢网络发生了显著改变,包括关键的脂肪酶 PNLIP、CLPS、PNLIPRP1 和 PNLIPRP2。与非肿瘤组织相比,这些脂肪酶在胰腺肿瘤中的表达显著降低,导致 FFA 减少。更重要的是,两个独立队列的肿瘤中 PNLIP 的基因表达越低,生存情况越差。我们进一步表明,两种饱和脂肪酸,棕榈酸和硬脂酸,显著诱导 TRAIL 表达,触发胰腺癌细胞凋亡并抑制增殖。
我们的结果表明,涉及脂肪酶的脂肪分解途径和一组独特的 FFA 的损伤可能在胰腺癌的发生和发展中起重要作用,并为治疗干预提供了潜在的靶点。